Riquent: Withdrawal of the marketing authorisation application

abetimus

Overview

On 13 October 2006, La Jolla Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Riquent, for the treatment of lupus nephritis.

  • List item

    Questions and answers on the withdrawal of the marketing application for Riquent (PDF/39.66 KB)


    First published: 18/10/2006
    Last updated: 18/10/2006
    EMEA/410799/2006

  • Key facts

    Name
    Riquent
    Product number
    EMEA/H/C/000733
    International non-proprietary name (INN) or common name
    • abetimus
    Active substance
    • abetimus
    Date of withdrawal
    13/10/2006
    Company making the application
    La Jolla Limited
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating